False amoxicillin/clavulanic acid susceptibility in Bacteroides fragilis using gradient strip tests.


Journal

Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 15 10 2020
revised: 01 03 2021
accepted: 12 03 2021
pubmed: 21 3 2021
medline: 27 11 2021
entrez: 20 3 2021
Statut: ppublish

Résumé

Repeatedly, too low MIC results were obtained in Bacteroides fragilis quality assessment strains, using gradient strip tests with a ratio of amoxicillin:clavulanic acid of 2:1. We aimed to find the most accurate available gradient strip tests for susceptibility testing of amoxicillin/clavulanic acid in B. fragilis in comparison with agar dilution with EUCAST methodology and breakpoints. Twenty-seven clinical B. fragilis isolates were investigated using gold standard EUCAST amoxicillin/clavulanic acid agar dilution (fixed clavulanic acid concentration at 2 mg/L, with increasing amoxicillin concentrations) as well as three commercial gradient strip tests: XL (ratio), AUG (ratio) or AMC (fixed concentration). Using agar dilution (fixed concentration), 19 isolates were susceptible, 1 isolate was susceptible increased exposure (I) and 7 isolates were resistant. Categorical agreement of the gradient strip tests with agar dilution (fixed concentration) was 70% for XL (ratio), 71% for AUG (ratio) and 89% for AMC (fixed concentration). Very major error rates in comparison with agar dilution (fixed concentration) were 100%, 0%, and 0%, respectively. EUCAST breakpoint usage in amoxicillin/clavulanic acid susceptibility tests for B. fragilis should be accompanied by EUCAST methodology. When using alternative methods such as gradient strip tests, a higher degree of alignment with EUCAST methodology, such as using fixed clavulanic acid concentrations, improves precision.

Sections du résumé

BACKGROUND BACKGROUND
Repeatedly, too low MIC results were obtained in Bacteroides fragilis quality assessment strains, using gradient strip tests with a ratio of amoxicillin:clavulanic acid of 2:1. We aimed to find the most accurate available gradient strip tests for susceptibility testing of amoxicillin/clavulanic acid in B. fragilis in comparison with agar dilution with EUCAST methodology and breakpoints.
METHODS METHODS
Twenty-seven clinical B. fragilis isolates were investigated using gold standard EUCAST amoxicillin/clavulanic acid agar dilution (fixed clavulanic acid concentration at 2 mg/L, with increasing amoxicillin concentrations) as well as three commercial gradient strip tests: XL (ratio), AUG (ratio) or AMC (fixed concentration).
RESULTS RESULTS
Using agar dilution (fixed concentration), 19 isolates were susceptible, 1 isolate was susceptible increased exposure (I) and 7 isolates were resistant. Categorical agreement of the gradient strip tests with agar dilution (fixed concentration) was 70% for XL (ratio), 71% for AUG (ratio) and 89% for AMC (fixed concentration). Very major error rates in comparison with agar dilution (fixed concentration) were 100%, 0%, and 0%, respectively.
CONCLUSIONS CONCLUSIONS
EUCAST breakpoint usage in amoxicillin/clavulanic acid susceptibility tests for B. fragilis should be accompanied by EUCAST methodology. When using alternative methods such as gradient strip tests, a higher degree of alignment with EUCAST methodology, such as using fixed clavulanic acid concentrations, improves precision.

Identifiants

pubmed: 33741507
pii: S1075-9964(21)00041-X
doi: 10.1016/j.anaerobe.2021.102358
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Reagent Strips 0
Amoxicillin-Potassium Clavulanate Combination 74469-00-4

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102358

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Rob J Rentenaar (RJ)

Department of Medical Microbiology, University Medical Center Utrecht, Internal mail no G.04.614, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands. Electronic address: r.j.rentenaar@umcutrecht.nl.

Bianca Bovo-Heijmans (B)

Department of Medical Microbiology, University Medical Center Utrecht, Internal mail no G.04.614, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.

Joanna Diggle (J)

Specialist Antimicrobial Chemotherapy Unit, Microbiology Cardiff, Public Health Wales, University Hospital of Wales, Heath Park, CARDIFF CF14 4XW, UK.

Ad C Fluit (AC)

Department of Medical Microbiology, University Medical Center Utrecht, Internal mail no G.04.614, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.

Mandy Wootton (M)

Specialist Antimicrobial Chemotherapy Unit, Microbiology Cardiff, Public Health Wales, University Hospital of Wales, Heath Park, CARDIFF CF14 4XW, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH